2017 American Society of Hematology Annual Meeting*

December 9-12, 2017; Atlanta, Georgia
Review expert perspectives on key findings on novel targeted therapies in hematologic malignancies presented at the 2017 ASH annual meeting.
Farrukh Awan, MD, MS
Daniel J. DeAngelo, MD, PhD
Madeleine Duvic, MD
Marie Anne Scully, MD

Novel Targeted Therapies in Hematologic Malignancies

At a median follow-up of 33.9 months, brentuximab vedotin showed superior outcomes and durable responses vs either methotrexate or bexarotene for patients with previously treated, CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma.

Released: December 20, 2017

Avapritinib was well tolerated and safe across several dose levels with an ORR of 72% by IWG-MRT-ECNM criteria.

Released: December 20, 2017

Novel chemotherapy-free combination of avadomide plus obinutuzumab tolerable and active in patients with relapsed/refractory NHL.

Released: December 12, 2017

The combination of acalabrutinib and obinutuzumab yielded ORR rates exceeding 90% that deepened over time, along with a favorable safety profile.

Released: December 15, 2017

Mogamulizumab approximately doubled median PFS compared with vorinostat in patients with previously treated CTCL.

Released: December 19, 2017

In this expert analysis of key data from the Hematology 2017 annual meeting, the clinical implications of new targeted therapeutic strategies in multiple hematologic diseases (NHL, CLL, CTCL, systemic mastocytosis, and acquired TTP) are reviewed by Farrukh Awan, MD, MS; Madeleine Duvic, MD; Daniel J. DeAngelo, MD, PhD; and Marie Ann Scully, MD.

Farrukh Awan, MD, MS Daniel J. DeAngelo, MD, PhD Madeleine Duvic, MD Marie Anne Scully, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: February 16, 2018 Expiration: February 15, 2019

Composite of aTTP-related death, aTTP recurrence, and major thromboembolic events significantly reduced with caplacizumab vs placebo.

Released: December 19, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?